NMD Pharma to Present Data on its Skeletal Muscle Targeted Therapy for Rare Neuromuscular Diseases at the 2024 AANEM Annual Meeting
11 oct. 2024 07h00 HE
|
NMD Pharma
NMD Pharma to Present Data on its Skeletal Muscle Targeted Therapy for Rare Neuromuscular Diseases at the 2024 AANEM Annual Meeting Aarhus, Denmark, 11 October 2024 – NMD Pharma A/S, a...
NMD Pharma to Present Data on its Skeletal Muscle Targeted Therapy for Rare Neuromuscular Diseases at the 2024 AANEM Annual Meeting
11 oct. 2024 01h00 HE
|
NMD Pharma
NMD Pharma to Present Data on its Skeletal Muscle Targeted Therapy for Rare Neuromuscular Diseases at the 2024 AANEM Annual Meeting Aarhus, Denmark, 11 October 2024 – NMD Pharma A/S, a...
Nucleic Acid Therapeutics CDMO Industry Outlook, 2024-2030 - Increasing Demand for One-Stop-Shop CDMOs and Growing FDIs in Nucleic Acid Therapeutics
10 oct. 2024 12h30 HE
|
Research and Markets
Dublin, Oct. 10, 2024 (GLOBE NEWSWIRE) -- The "Nucleic Acid Therapeutics CDMO Market Size, Share & Trends Analysis, 2024-2030" report has been added to ResearchAndMarkets.com's offering.The...
Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation
10 oct. 2024 01h00 HE
|
Pharming Group N.V.
Proof of concept clinical trial will evaluate leniolisib in PIDs with immune dysregulation linked to altered PI3Kẟ signaling in lymphocytes PIDs to include ALPS-FAS, CTLA4 haploinsufficiency, NFKB1...
Catalyst Pharmaceuticals Donates $100,000 to the American Red Cross Hurricane Helene Relief Efforts
08 oct. 2024 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "the Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on...
New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA
08 oct. 2024 07h30 HE
|
Biogen Inc.
Findings from Part B and Part C of the DEVOTE study support the clinical benefits of a higher dose regimen of nusinersen (50/28 mg) in both individuals previously treated and treatment-naïve to...
Catalyst Pharmaceuticals to Participate in the BofA Securities CNS Therapeutics Virtual Conference 2024
01 oct. 2024 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
CLINUVEL files Canadian New Drug Submission for SCENESSE® in EPP
30 sept. 2024 19h07 HE
|
Clinuvel Pharmaceuticals Limited
CLINUVEL has filed a Canadian New Drug Submission for SCENESSE® (afamelanotide) for erythropoietic protoporphyria (EPP).
OMEICOS Therapeutics Completes Enrollment of PMD-OPTION Study in Primary Mitochondrial Disease
26 sept. 2024 06h00 HE
|
OMEICOS Therapeutics GmbH
Interim data confirms OMT-28’s strong safety profile in PMD patients, top-line data expected mid-2025 BERLIN, GERMANY, September 26, 2024 – OMEICOS, a biopharmaceutical company developing...
Pharming announces marketing authorization in the U.K. for Joenja® (leniolisib)
26 sept. 2024 01h00 HE
|
Pharming Group N.V.
For media and investors only Indicated for adult and pediatric patients 12 years of age and older with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) Leiden, the...